China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) is set to transfer the patent and other rights to its hypidone (HHT001), an innovative antidepressant co-developed by the Academy of Military Medical Sciences’ (AMMS) toxicity and drug institute. The transfer will be conducted through a public listing on the China Technology Exchange.
Drug Profile and Development
HHT001 is a Category 1.1 drug, with compound patent rights owned by AMMS and clinical approvals held by both Huahai Pharmaceutical and AMMS. The drug has successfully completed Phase IIb clinical trials, demonstrating its potential as a novel treatment for depression.
Significance of the Public Listing
The public listing of HHT001’s patent and rights on the China Technology Exchange marks a significant step in the commercialization of this innovative antidepressant. This move is expected to attract further investment and support for the development and distribution of HHT001, potentially bringing a new and effective treatment option to patients suffering from depression.-Fineline Info & Tech
